8 research outputs found
TCT-164 Assessment of the efficacy of ex vivo platelet transfusion in the restoration of platelet function in acute coronary syndrome and PCI presenters treated with clopidogrel, prasugrel or ticagrelor - The APTITUDE study
TCT-748 Double The Dose Of Clopidogrel Or Switch To Prasugrel To Antagonize Proton Pump Inhibitor Interaction
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry.
THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin. The present study aimed to describe the proportion of patients eligible and reasons for ineligibility for THEMIS within a population of patients with diabetes and CAD included in the Reduction of Atherothrombosis for Continued Health (REACH) registry.
The THEMIS eligibility criteria were applied to REACH patients. THEMIS included patients ≥50 years with type 2 diabetes and stable CAD as determined by either a history of previous percutaneous coronary intervention, coronary artery bypass grafting, or documentation of angiographic stenosis of ≥50% of at least one coronary artery. Patients with prior myocardial infarction or stroke were excluded. In REACH, 10,156 patients had stable CAD and diabetes. Of these, 6515 (64.1%) patients had at least one exclusion criteria. From the remaining population, 784 patients did not meet inclusion criteria (7.7%) mainly due to absence of aspirin treatment (7.2%), yielding a 'THEMIS-eligible population' of 2857 patients (28.1% of patients with diabetes and stable CAD). The main reasons for exclusion were a history of myocardial infarction (53.1%), use of oral anticoagulation (14.5%), or history of stroke (12.9%). Among the 4208 patients with diabetes and a previous PCI, 1196 patients (28.4%) were eligible for inclusion in the THEMIS-PCI substudy.
In a population of patients with diabetes and stable coronary artery disease, a sizeable proportion appear to be 'THEMIS eligible.'
http://www.
gov identifier: NCT01991795.The THEMIS trial was funded by AstraZeneca. The REACH registry
was sponsored by Sanofi, Bristol-Myers Squibb, and the Waksman
Foundation (Tokyo, Japan) and is endorsed by the World Heart
Federation.S
Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registry
Background:
Conflicting data exist on the association between consumption of coffee or tea and cardiovascular outcomes, and few focus on patients with established coronary artery disease.
Aim:
To describe the association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease, using an extensive contemporary international registry, allowing the identification of multiple potential confounders.
Methods:
The Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) registry enrolled in 2009 and 2010 in 45 countries, with a 5-year follow-up. Patients were categorized according to daily consumption of coffee or tea, and were compared with those declaring neither. The primary composite outcome of myocardial infarction, stroke or cardiovascular death was analysed at 5years, as well as all-cause mortality. Sensitivity analyses were performed with a multivariable model.
Results:
A total of 15,459 and 10,029 patients declared coffee or tea consumption, respectively. At 5years, after full adjustment, no association was found between coffee consumption and the primary outcome: hazard ratio 1.04 (95% confidence interval 0.89-1.21) for 1 cup; 0.94 (0.82-1.08) for 2-3 cups; and 1.04 (0.86-1.27) for ≥4 cups (P=0.51). Drinking tea was not associated with a different incidence of the primary outcome before or after adjustment, with fully adjusted hazard ratios of 1.08 (95% confidence interval 0.84-1.38) for 1 cup, 1.12 (0.96-1.31) for 2-3 cups and 0.95 (0.79-1.14) for ≥4 cups (P=0.30). After full adjustment, neither coffee nor tea drinking was associated with all-cause mortality.
Conclusions:
In outpatients with stable coronary artery disease, there was no association between coffee or tea consumption and ischaemic outcomes or all-cause mortality
TCT-748 Double The Dose Of Clopidogrel Or Switch To Prasugrel To Antagonize Proton Pump Inhibitor Interaction
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial
Recommended from our members
Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial
Few data are available on procedural complications of percutaneous coronary intervention (PCI) in the setting of acute coronary syndrome in the contemporary era.
We sought to describe the prevalence of procedural complications of PCI in a non-ST-segment elevation acute coronary syndrome (NSTE ACS) cohort, and to identify their clinical characteristics and association with clinical outcomes.
Patients randomized in TAO (Treatment of Acute coronary syndrome with Otamixaban), an international randomized controlled trial (ClinicalTrials.gov Identifier: NCT01076764) that compared otamixaban with unfractionated heparin plus eptifibatide in patients with NSTE ACS who underwent PCI, were included in the analysis. Procedural complications were collected prospectively, categorized and adjudicated by a blinded Clinical Events Committee, with review of angiograms. A multivariable model was constructed to identify independent clinical characteristics associated with procedural complications.
A total of 8656 patients with NSTE ACS who were enrolled in the TAO trial underwent PCI, and 451 (5.2%) experienced at least one complication. The most frequent complications were no/slow reflow (1.5%) and dissection with decreased flow (1.2%). Procedural complications were associated with the 7-day ischaemic outcome of death, myocardial infarction or stroke (24.2% vs. 6.0%, odds ratio 5.01, 95% confidence interval 3.96–6.33; P<0.0001) and with Thrombolysis In Myocardial Infarction major and minor bleeding (6.2% vs. 2.3%, odds ratio 2.79, 95% confidence interval 1.86–4.2; P<0.0001). Except for previous coronary artery bypass grafting, multivariable analysis did not identify preprocedural clinical predictors of complications.
In a contemporary NSTE ACS population, procedural complications with PCI remain frequent, are difficult to predict based on clinical characteristics, and are associated with worse ischaemic and haemorrhagic outcomes.
Peu de données sont disponibles sur les complications procédurales de l’angioplastie coronaire percutanée (ICP) dans le cadre des SCA à l’ère contemporaine. Nous avons cherché à décrire la prévalence des complications procédurales de l’ICP dans une cohorte de SCA sans élévation du segment ST (NSTE ACS) et à identifier leurs caractéristiques cliniques et leur association avec les évènements cliniques.
Les patients randomisés dans TAO (Treatment of Acute Coronary Syndrome with Otamixaban), un essai contrôlé randomisé international comparant l’otamixaban à l’héparine non fractionnée plus l’eptifibatide chez les patients atteints de NSTE ACS et ayant bénéficié d’une ICP, ont été inclus dans l’analyse. Les complications procédurales ont été collectées, catégorisées et évaluées de manière prospective en aveugle, avec examen des angiogrammes, par un comité des événements cliniques. Une analyse multivariée a été construite afin d’identifier les caractéristiques cliniques indépendantes associées aux complications procédurales.
Un total de 8656 patients traités pour un NSTE ACS qui étaient inclus dans l’essai TAO a bénéficié d’une ICP et 451 (5,2 %) a présenté au moins une complication. Les plus fréquentes étaient : no/slow flow (1,5 %) et les dissections avec altération du flux (1,2 %). À 7 jours, les complications procédurales étaient associées à une augmentation du critère de jugement ischémique composé de décès, infarctus du myocarde et AVC (25,1 % contre 6,8 %, OR [IC à 95 %] : 1,50 [1,08–2,10], p<0,0001) et des hémorragies TIMI majeures et mineures (6,8 % contre 2,3 %, OR [IC à 95 %] : 2,79 [1,86–4,2], p<0,0001). À l’exception d’un antécédent de pontage aortocoronaire, l’analyse multivariée n’a pas identifié de facteurs cliniques pré-procéduraux prédictifs de complications.
Dans une population contemporaine de NSTE ACS, les complications procédurales de l’ICP restent fréquentes, sont difficiles à prédire à l’aide des seules caractéristiques cliniques et sont associées à un surplus d’évènements ischémiques et hémorragiques